(Credit: MedPharm)
MedPharm, a company specializing in topical and transdermal development, has licensed its MedSpray technology to Malvern, PA-based Virpax Pharmaceuticals, a developer of pharmaceutical products for pain management through new drug delivery systems.
The MedSpray technology, which is covered by worldwide patents, delivers transdermal patch technology in a metered-dose aerosol spray. The thin film patch created on the skin or mucosal membrane has been demonstrated in clinical trials to provide long-lasting efficacy for patients.
The company is working closely with Virpax to develop DSF100 (NSAID spray film 1.3%), an investigational spray film designed to deliver an NSAID transdermally via a metered-dose spray. The delivery system features a high level of adhesiveness, accessibility, and skin drying. Virpax filed a pre-IND meeting request with the U.S. Food and Drug Administration (FDA) and it was granted on May 18, 2018.
“We believe there is an opportunity to explore the development of non-opioid transdermal pain treatments that improve on existing gel and patch products, for which adhesion and accessibility can be a challenge,” said Anthony Mack, CEO of Virpax. “We believe that the ‘Patch-in-a-Can’ technology offers a promising delivery system.”
MedPharm, headquartered in Guildford, UK, maintains R&D centers in the U.S. and U.K.
(Source: MedPharm)
